CSIMarket
 
Prophase Labs Inc   (PRPH)
Other Ticker:  
 
 
Price: $5.0400 $0.18 3.704%
Day's High: $5.1928 Week Perf: 2.65 %
Day's Low: $ 4.47 30 Day Perf: 0.2 %
Volume (M): 27 52 Wk High: $ 9.94
Volume (M$): $ 138 52 Wk Avg: $5.98
Open: $4.47 52 Wk Low: $4.05



 Market Capitalization (Millions $) 87
 Shares Outstanding (Millions) 17
 Employees 24
 Revenues (TTM) (Millions $) 62
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -22
 Capital Exp. (TTM) (Millions $) 3

Prophase Labs Inc
Prophase Labs Inc is a publicly-traded, leading vertically-integrated health and wellness company headquartered in Doylestown, Pennsylvania, USA. The company is engaged in the research, development, manufacture and marketing of over-the-counter (OTC) healthcare and dietary supplements. It operates through two segments: Prophase Laboratories, which focuses on the development of OTC cold remedy products, and Prophase Diagnostics, which specializes in developing and distributing diagnostic test kits.

Prophase Labs began its operations in 1988 and has since then grown to become a significant player in the health and wellness industry. Its flagship product, the Cold-EEZEe brand, a zinc gluconate glycine product, is a top-selling cold remedy in the United States. The company is focused on leveraging its research and development capabilities to create innovative products that address the changing needs of consumers. It does this by researching market trends, monitoring consumer preferences, and identifying emerging health concerns.

Prophase Labs is vertically integrated, with a state-of-the-art manufacturing plant that produces its own products. This enables the company to have greater control over the quality of its products, reduce costs and improve supply chain efficiency. Additionally, the company has a proven track record for achieving regulatory approvals from the US Food and Drug Administration (FDA) for its products.

The company's commitment to innovation is reflected in the significant investment it has made in its research and development (R&D) capabilities. Prophase Labs employs a team of scientists, technicians and quality control personnel who work in its in-house R&D laboratory. This group is responsible for developing new products, reformulations, and improving existing products. The company invests significant resources in R&D to stay ahead of the competition and bring innovative and clinically-proven products to the market.

Apart from its OTC healthcare products, Prophase Labs has also ventured into the distribution of diagnostic test kits through its ProPhase Diagnostics segment. The company distributes a wide range of COVID-19 diagnostic test kits and has partnered with leading manufacturers to provide quality products to its customers.

Prophase Labs is committed to providing high-quality products to its customers while maintaining ethical business practices. The company has a code of conduct for its employees and partners that outlines its values and principles. It also has various sustainability initiatives that aim to minimize its impact on the environment.

In conclusion, Prophase Labs is a leading vertically-integrated health and wellness company that is committed to providing innovative, high-quality products to its customers. With its focus on research and development, vertical integration, and commitment to ethical business practices, the company is well-positioned to continue its growth and success in the dynamic health and wellness industry.


   Company Address: 711 Stewart Ave Garden City 11530 NY
   Company Phone Number: 345-0919   Stock Exchange / Ticker: NASDAQ PRPH
   PRPH is expected to report next financial results on March 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Prophase Labs Inc

Prophase Labs Inc. Faces Unprecedented Reporting Quarter; Braces for Demanding July-September 2023 Period



Prophase Labs Inc, a major player in the pharmaceutical preparations industry, recently disclosed abysmal financial results for the period spanning July to September 2023. The company has witnessed a significant decline in revenue, an alarming increase in net deficit per share, and a substantial rise in inventory levels. These distressing indicators, along with the plummeting stock price, paint a bleak picture for the company's future prospects.
1. Plummeting Revenue:
Prophase Labs Inc has experienced a colossal decline in revenue during the previous reporting season, with figures dropping by a staggering -65.591% to a mere $8.33 million. This steep decline is amplified when compared to the corresponding period a year prior, where revenue already suffered a -33.106% fall from $12.45 million. This downward spiral hints at a concerning trend and raises serious questions about the company's ability to generate sustainable income.

Prophase Labs Inc

Prophase Labs Inc Faces Major Financial Setback: Red Alert at PRPH during Q2 2023!

Prophase Labs Inc, a pharmaceutical company, reported a financial loss in the second quarter of 2023. The company slipped into a loss of -$0.20 per share compared to a profit of $0.40 per share in the same quarter of the previous year. Additionally, earnings per share fell from $0.03 in the previous quarter. These figures indicate a concerning decline in profitability for the company.
One of the main contributors to the financial loss was a sharp drop in revenue. The company experienced a significant decrease of -57.212% in revenue, which amounted to $12.45 million in the second quarter of 2023. This is in stark contrast to the $29.09 million in revenue generated in the corresponding quarter of the previous year. Furthermore, the revenue also tumbled by -35.513% from the previous quarter, where revenue stood at $19.30 million. These figures highlight the challenges and difficulties that Prophase Labs Inc faced during this period.

Prophase Labs Inc

Prophase Labs Inc Faces Financial Plunge with -95.59% Income Drop in Q1 2023

Prophase Labs Inc, a healthcare company, has been struggling with its revenue per employee. The latest trailing twelve month data shows that it fell to $3,934,125. This decline in revenue can be concerning for the shareholders of the company. However, Prophase Labs Inc has managed to maintain productivity levels above the average within the company despite the decline in revenue per employee.
According to the latest financial report, Prophase Labs Inc has 24 employees. Among the company's peers within the healthcare sector, 11 other companies have achieved a higher revenue per employee. This means that Prophase Labs Inc has some catching up to do to remain competitive within the industry.






 

Prophase Labs Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com